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Background: Despite the existence of effective treatment, tuberculosis is still a global public health issue. The
World Health Organization recommends a six-month four-drug regimen in fixed-dose combination formulation to
treat drug sensitive tuberculosis, and long course regimens with several second-line drugs to treat multi-drug
resistant tuberculosis. To achieve the projected tuberculosis elimination goal by 2050, it will be essential to ensure a
non-interrupted supply of quality-assured tuberculosis drugs. However, quality and affordable tuberculosis drug
supply is still a significant challenge for National Tuberculosis Programs.
Discussion: Quality drug production requires a combination of complex steps. The first challenge is to guarantee
the quality of tuberculosis active pharmaceutical ingredients, then ensure an adequate manufacturing process,
according to international standards, to guarantee final product´s safety, efficacy and quality. Good practices for
storage, transport, distribution and quality control procedures must follow. In contrast to other high-burden
countries, Brazil produces tuberculosis drugs through a strong network of public sector drug manufacturers
regulated by a World Health Organization-certified national sanitary authority. The installed capacity for production
surpasses the 71,000 needed treatments in the country. However, in order to be prepared to act as a global
supplier, important bottlenecks are to be overcome. This article presents an in-depth analysis of the current status
of production of tuberculosis drugs in Brazil and the bottlenecks and opportunities for the country to sustain
national demand and play a role as a potential global supplier. Raw material and drug production, quality control,
international certification and pre-qualification, political commitment and regulatory aspects are discussed, as well
recommendations for tackling these bottlenecks. This discussion becomes more important as new drugs and
regimens to treat tuberculosis are expected in a close future.
Summary: International manufacturers of raw material for tuberculosis treatment should undergo certification and
pre-qualify their active pharmaceutical ingredients as a first step to ensure quality of tuberculosis drugs. At the
country level, Brazilian public manufacturers should apply for international certification and tuberculosis drugs
should be pre-qualified by international organisms. Finally, only with political commitment and large-scale
production will Brazilian public sector manufacturers be able to partially supply the global market.
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The World Health Organization (WHO) estimates that one
third of the world population is infected by M. tuberculosis.
WHO also estimates that in 2010, 8.7 million (range 8.3-
9.0 million) people developed tuberculosis (TB) and 0.99
million (range 0.84-1.1 million) died from TB, with 0.43
million (range 0.40-0.46 million) additional deaths from
HIV-associated TB. [1] Worldwide, TB is the second lead-
ing cause of death from infectious diseases [1] and the first
among people living with HIV/Aids. [2] To combat TB
worldwide, the United Nations [3] and WHO [4] propose
that by 2050, TB global incidence rate should decrease to
less than 1/1,000,000 inhabitants per year. By 2015, global
targets aim to reduce global TB prevalence and death rates
by 50% compared to 1990 [3].
Among other challenges, the rapid spread of drug re-
sistant TB in Africa, Eastern Europe and Asia [5,6] jeop-
ardizes the achievement of these goals [1]. Drug
resistant strains emerged mainly from the inadequate
use of TB drugs, or use of low quality drugs, poor TB
program performance and lack of regulation [7]. The in-
corporation at country level of promising advances on
new drug, vaccine and diagnostic technologies will still
take time before they can effectively contribute to global
TB control [8,9]. In the meantime, it is important to
guarantee an uninterrupted supply of quality-assured
drugs at the country level.
This article will introduce key issues on the Brazilian
model for TB control and focus on the production of
quality TB drugs in Brazil, highlighting current strengths
and obstacles of the Brazilian Public Pharmaceutical
Manufacturing Laboratories (PPML) [10] as potential sup-
pliers for the global market.
Discussion
Specificities of Brazilian Context for TB Control
Brazil is one of the 22 countries that account for 80% of
the global burden of TB [1]. In 2010, the country
reported 71,337 new TB cases [1]. In Brazil, TB treat-
ment is offered exclusively in the public sector, according
to current rules and treatment protocols recommended
by the Ministry of Health (MoH) [11]. Public manufac-
turers provide TB drugs, including fixed-dose combin-
ation (FDC) of rifampicin and isoniazid since the 1970s,
[9] which are distributed free of charge across the country
[12]. The drugs are purchased centrally by the MoH and
distributed to the municipalities [13]. Except for quinolones
and aminoglycosides, TB drugs are not available in private
pharmacies; they are exclusively distributed in the public
health system. Treatment of TB is based on national rec-
ommendations and guidelines edited jointly by the MoH
and professional associations [11,14]. There is no private
market for TB drugs or TB treatment. As a consequence,
the rate of multidrug-resistant TB in the country hasremained low (1.4%, personal communication by Brazilian
National TB Control Program (NTP), based on national
survey conducted in 2008–2009).
Opportunities for TB drug manufacturing in Brazil
Drug production is regulated by Brazil’s National Regulation
Authority (ANVISA) [15]. ANVISA was established in
1999 to regulate health products and services in Brazil, fol-
lowing the model of international regulation authorities,
[15] and is WHO pre-qualified for regulation of vaccine
production [15]. The PPML produce 11 billion pharma-
ceutical units per year to meet the needs of government-
run public health programs [10,16]. This manufacturing
network has improved technologically and gained recogni-
tion through its broadly acknowledged capacity for anti-
retroviral production [13,17]. First-line TB drugs, including
fixed dose combination formulations, and some second-
line TB drugs are currently manufactured by these PPML.
[17] Farmanguinhos, one of the most innovative manufac-
turers of this network, developed the Rifampicin/Isoniazid
(RH) 2:1 FDC tablet (currently undergoing registration
process) and is working on the pharmacotechnical de-
velopment of the Rifampicin/Isoniazid/Pyrazinamide/
Ethambutol (RHZE) 4:1 FDC, through a public-private
partnership (PPP) agreement with a WHO-pre-qualified
Indian manufacturer [18].
Under this new context, PPML produce TB drugs with
formulations and dosages/strengths aligned with WHO rec-
ommendations, opening new opportunities to supply the
international market [17]. Entering the global supply chain
would likely contribute to leverage production scale, and
maintenance of quality standards without significant extra
costs. However, in order to reach international certification
requirements, like compliance to WHO’s pre-qualification
program, [19] and attain financial sustainability, a few bot-
tlenecks should be overcome.
Bottlenecks for TB drug manufacturing in Brazil
Economic incentives for production
The costs of drugs and the impact of imported supplies on
the national trade balance are important issues for the sus-
tainability of any public health system, often influencing
priorities for investment. However, the majority of TB
drugs are available at low cost in national and international
markets [10,20] and therefore have limited budgetary im-
pact for the Brazilian National Health System (Sistema
Único de Saúde - SUS) [21]. Thus, most TB drugs have
low commercial interest for manufacturers, [10,20] includ-
ing PPML. More expensive second-line drugs, such as
capreomycin, cycloserin/terezidon, 4-aminosalicylic acid
(PAS) or ultimate generation quinolones, at least while
they are not part of first-line regimen, are also not con-
sidered a priority for local production, because of
Brazil’s low drug resistance rates and limited demand.
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most innovative technological approaches to maximize
return on investments. The same logic applies to the
public sector based industry, which frequently chooses
to produce, promote and fund innovation focusing on
high-cost drugs that can boost revenues for the PPML,
and reduce costs for the health system [10,22]. TB drugs
do not represent such an incentive [21,23].
Nevertheless, TB is a national and global priority [10].
It is critical to engage diverse stakeholders, including
regulatory agencies, media, civil society and political or-
ganizations to support domestic production of TB drugs
in Brazil. Even if not profitable, domestic production
would benefit job creation, technological development
and supply security, and above all, meet an important
public health need.
Active pharmaceutical ingredients (API)
Manufacturing of most molecules employed in TB treat-
ment does not impose significant technological challenges
[24]. In addition to international API manufacturers dir-
ectly linked to large pharmaceutical companies, countless
independent medium-sized companies manufacture API.
However, challenges remain, including an economic disin-
centive (due to low cost and low demand) and gaps in the
parameters and mechanisms to guarantee API quality
standards [25]. Limited official control from national and
international regulatory agencies also leads to highly vari-
able quality of API [1,19,23]. This severely impacts the
quality of final products and production consistency.
In order to guarantee drug quality, physicochemical and
microbiological characteristics of API must be standardized
and kept constant, [24] through an expanded certification
process. Certification should be based on specific descrip-
tion of quality parameters for API, and pre-qualification of
raw materials is an essential step for the manufacturing of
quality drugs [25,26]. Private industries ensure compliance
and consistency by establishing supplier-manufacturer
agreements. However, Brazilian PPML must follow public
sector procurement rules, [27] and government regulations
prohibit procurement notices conditioned to specific tech-
nical requirements. This has occasionally made it difficult
for PPML to purchase critical pharmaceutical ingredients
in accordance with characteristics approved by the health
regulatory agencies, or to establish a consistent relationship
with a selected supplier. These legal procurement aspects,
as they apply to API, may hamper the uniformity of nation-
ally manufactured drugs.
The manufacturing process
Drug quality control, whether carried out by the private
industry or by the national regulatory inspection frame-
work, involves a set of legal, technical and administrative
requirements [24,28]. In Brazil, quality control is insuredby the Brazilian Sanitary Surveillance System, headed by
the Brazilian National Institute of Metrology [29] and
ANVISA [15]. One potential limiting factor of this highly
regulated sector is the availability of reference materials
for bioavailability and bioequivalence studies in the na-
tional market [30]. In addition, standardized proficiency
testing programs must be carried out on a regular basis.
Although the government implemented a dedicated qual-
ity control program for TB drugs in 2005, [31] and refer-
ence substances were prioritized for local development by
the Brazilian Pharmacopeia, [30] strong political will and
support are necessary to ensure the continuation of such a
program. Additionally, it is critical to ensure effective
mechanisms for drug certification [25].Internal technological development
Over the last few decades, Brazil has increased its invest-
ment in scientific and technological innovation. Numerous
examples can be found in other fields of knowledge, such
as the country’s expanded participation in the petroleum/
biodiesel and agricultural global markets [32]. This invest-
ment has also led to growth in scientific publications
around health, including scholarships and research grants
for TB projects [33].
In the past decade, Brazil identified the pharmaceutical
sector as a priority for industrial policy [34]. PPPs
supporting technology transfers from international com-
panies to domestic public sector manufacturers are a
core strategy of that policy. The consolidated experience
of the numerous PPPs coupled with national investment
in development of new technologies by Brazilian investi-
gators represent an important push for pharmaceutical
innovation in the country.
Despite these recent efforts, significant investment is
still needed. In the 1990s, rapid changes in importation
policies led to a lack of prioritization of industrial drug
manufacturing capacity, which had been strengthened
under previous national development cycles [34]. This
created a gap in pharmaceutical research and develop-
ment capabilities that is still felt today. Going forward,
progress will require strong science and technology pol-
icies that encourage later-stage pharmaceutical-technical
development and industrial-scale drug manufacturing.Recommendations for addressing the identified
bottlenecks
Economic incentives for production
The SUS strategic product policy could incorporate
some of the innovative thinking developed through na-
tional and international initiatives such as the Drugs for
Neglected Disease Initiative program [35]. To incentivize
drug development, this program successfully balanced
economic interests and public health needs, including
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regarding these drugs.
Brazil has been playing an important role in South-South
cooperation on health and other development sectors [36].
This has enhanced the country’s political credibility world-
wide, and could facilitate access to global markets for do-
mestically-produced TB drugs. Since national demand for
TB drugs is relatively limited in scale, participating in
international markets through global initiatives would help
justify required investments, benefiting manufacturing
capacity overall. Additionally, product development ef-
forts focusing on needed innovations for TB control,
such as paediatric, geriatric as well as parenteral formula-
tions, may further expand the potential international
market for PPML.
Finally, if PPML are fully compliant with international
requirements for drug quality, innovative models guar-
anteeing advanced purchase commitments from inter-
national mechanisms would facilitate Brazil engagement
for investing in TB drug production.
API
The legal requirements regarding the bidding process for
API in Brazil need to be revisited to address the PPML
specificities and to incorporate a new legal paradigm to
increase efficiency for public sector companies. This will
require strong political advocacy and commitment, along
with improved harmonization across government agencies
to further define and adapt legal mechanisms and admin-
istrative processes to leverage suitable levels of efficiency
in API purchasing. In addition, it will be necessary to de-
fine requirements for API certification by national or
international organizations. TB API suppliers could be en-
couraged to register their quality, safety and efficiency
standards with national regulatory authorities. Issues to be
considered as part of the registration process should in-
clude detailed information on the different synthetic
routes, specific and significant toxicological impurities,
polymorphism among other physicochemical characteris-
tics, which would allow for comparison between API from
diverse manufacturers.
This process would allow Brazil and other manufacturing
countries to share key updated information on API sup-
pliers. Above all, this approach would enable the Brazilian
MoH to monitor API market dynamics so that in critical sit-
uations, such as when there are limited manufacturers or
competition for specific API, risks of shortages would be
minimized and overall API quality standards improved. If
WHO and other international organizations standardize and
expand their pre-qualification mechanisms, Brazil – and
other interested countries - should take part in the process.
If coordinated with WHO and other international orga-
nizations, this registration process would likely increase
API supplier interest in applying for health registration.The manufacturing process
The Brazilian government should encourage PPML to
apply for the WHO pre-qualification program [26] and ini-
tiate first and second-line drug regulatory registration pro-
cedures in other countries. This could be leveraged through
a more unified global strategy approach. In partnership
with key international stakeholders and donors, the Brazil-
ian government could develop a priority agenda for global
and regional production of TB drugs. In a short time span,
Brazil could play an important role in supplying TB drugs
to the international market, particularly given the orga-
nizational strengths of SUS [13] and the fact that standards
for good manufacturing practices (GMP) certification are
aligned with the international ones. Farmanguinhos, one of
the main PPML, is already GMP certified for some of its
products. So is the Navy Forces Laboratory (laboratório da
Marinha), a fluoroquinolone producer. This needs to be
expanded, monitored and encouraged so that it becomes a
model for drug development programs at other PPML.
Internal technological development
If Brazil wishes to play a significant role as a global TB
drug producer, it is essential to continue with the PPP
approach for technology transfer and take additional
measures to foster domestic investment on pharmaceut-
ical research and innovation.
Incentivizing more interaction between public sector
research institutes and pharmaceutical manufacturers
through the Brazilian TB Research Network [37] may be
an adequate approach to establish innovative partner-
ships. Moreover, lessons learned during the implementa-
tion of a quality-control program for TB drugs in Brazil
indicated that there is strong interest in more interac-
tions between the manufacturing sector and the national
regulation authority. A closer collaboration between
manufacturers and ANVISA would help address, as early
as possible, manufacturing challenges that may impact
quality of final products. If implemented, these measures
may provide the basis for later stage development pro-
cesses, in case new molecules currently under develop-
ment are launched as new drugs [38] and attract the
attention of the manufacturing sector.
Summary
Considering the technical capacity, regulation framework
and industrial network established by PPML, Brazil has a
strong potential for supplying TB drugs to the inter-
national market in the near future. However, several issues
and bottlenecks still need to be addressed. At the global
level, an important step is to ensure the availability of
quality API. Brazilian manufacturers should be allowed to
purchase of API exclusively from pre-qualified manufac-
turers, which will require new mechanisms for API certifi-
cation and procurement by the Brazilian agencies and
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laboratory network needs to seek broader recognition by
pursuing certification through international quality mech-
anisms like the WHO pre-qualification program. TB drug
production for international markets could also be in-
cluded in Brazil’s South-South cooperation agenda. In
addition to benefiting global access, these efforts would
provide synergistic effects to consolidate capacity for regu-
lar quality-assured TB drug production for Brazil’s own
domestic demand.
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